2.29
3.38%
-0.08
AC Immune SA stock is currently priced at $2.29, with a 24-hour trading volume of 160.43K.
It has seen a -3.38% decreased in the last 24 hours and a -21.03% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.39 pivot point. If it approaches the $2.25 support level, significant changes may occur.
Previous Close:
$2.37
Open:
$2.35
24h Volume:
160.43K
Market Cap:
$226.48M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-2.6815
EPS:
-0.854
Net Cash Flow:
$-68.17M
1W Performance:
-3.78%
1M Performance:
-21.03%
6M Performance:
-19.93%
1Y Performance:
+19.27%
AC Immune SA Stock (ACIU) Company Profile
Name
AC Immune SA
Sector
Industry
Phone
41 21 345 91 21
Address
EPFL Innovation Park, Building B, Lausanne
AC Immune SA Stock (ACIU) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-01-19 | Downgrade | UBS | Buy → Neutral |
Jan-04-19 | Initiated | UBS | Buy |
Apr-05-18 | Initiated | H.C. Wainwright | Buy |
Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
Oct-18-16 | Initiated | Credit Suisse | Outperform |
Oct-18-16 | Initiated | Jefferies | Buy |
Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
AC Immune SA Stock (ACIU) Latest News
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
GlobeNewswire Inc.
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Zacks Investment Research
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
Zacks Investment Research
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
Zacks Investment Research
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
Zacks Investment Research
AC Immune (ACIU) Upgraded to Buy: Here's Why
Zacks Investment Research
AC Immune SA Stock (ACIU) Financials Data
AC Immune SA (ACIU) Net Income 2024
ACIU net income (TTM) was -$60.14 million for the quarter ending December 31, 2023, a +18.99% increase year-over-year.
AC Immune SA (ACIU) Cash Flow 2024
ACIU recorded a free cash flow (TTM) of -$68.17 million for the quarter ending December 31, 2023, a +13.09% increase year-over-year.
AC Immune SA (ACIU) Earnings per Share 2024
ACIU earnings per share (TTM) was -$0.7095 for the quarter ending December 31, 2023, a +20.46% growth year-over-year.
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Essex Bio-Technology Limited, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
Cap:
|
Volume (24h):